BusinessStreetwise Reports Examines How One Analyst Says This Biotech Company Could Potentially 'Double'By Nasdaq OMXNov 15, 2017, 2:00 PM UTC
BusinessGalectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017By Nasdaq OMXNov 13, 2017, 2:01 PM UTC
BusinessImmuron Successfully Completes NASH Phase II Clinical Study MilestoneBy Nasdaq OMXNov 9, 2017, 2:01 PM UTC
BusinessMadrigal Pharmaceuticals Reports 2017 Third Quarter Financial ResultsBy Nasdaq OMXNov 9, 2017, 12:50 PM UTC
BusinessGalectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXNov 7, 2017, 1:15 PM UTC
BusinessMadrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver MeetingBy Nasdaq OMXOct 23, 2017, 11:00 AM UTC
BusinessGalectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH CirrhosisBy Nasdaq OMXOct 20, 2017, 12:30 PM UTC
